Predictive models for recurrence of prostate cancer after defi nitive therapy are essential for patient counseling, the rational application of neoadjuvant therapy, and clinical trial design. In 1998, we developed a nomogram based on serum prostate-specifi c antigen (PSA), clinical stage, and biopsy Gleason grade that calculates the 5-year freedom from PSA-defi ned progression after radical prostatectomy ( 1 ) . The nomogram has been independently validated in diverse patient populations ( 2 -4 ) . Currently, it is the most widely used disease-specifi c prediction tool in oncology ( 5 ) . Nomograms also exist for prostate cancer recurrence after external-beam radiotherapy and brachytherapy ( 6 , 7 ) .
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Despite the robust prognostic information contained within the nomogram, it has several limitations. The 5-year progression-free probability overestimates a man's probability of long-term cancer control because a substantial number of men will experience disease recurrence after maintaining an undetectable PSA level for 5 years or more after radical prostatectomy ( 8 ) . Since 1998, an association between the extent of cancer in systematic prostate biopsy specimens and disease recurrence has been reported ( 9 ) . Last, widespread PSA screening has resulted in a stage migration such that patients of a similar grade and stage treated recently have an improved prognosis compared with longer ago ( 8 , 10 , 11 ) . We have addressed these limitations in an updated and enhanced model by extending the predictions to 10 years, by including systematic biopsy results, and by enabling the predictions to be adjusted for the year of surgery. The 10-year progression-free probability more closely estimates the likelihood of cure because patients with an undetectable PSA level for 10 years after radical prostatectomy have a long-term progression rate of only 3% ( 8 Table 1 ). An external validation cohort consisted of 1545 patients who were treated by other surgeons at our institution during this time. The schedule by which patients were followed postoperatively has been described previously ( 8 ) . Disease progression was defi ned as a serum PSA value of 0.4 ng/mL or greater (confi rmed by a second PSA value higher than the fi rst by any amount), secondary therapy, clinical recurrence, or aborted radical prostatectomy for lymph node metastases ( 13 ) . Internal and external validation of the nomogram was performed using methods described previously ( 1 ) . Predictive accuracy was assessed using the concordance ( c -) index (discrimination) ( 14 ) and a visual inspection of the plots comparing the predicted probability of recurrence with the observed outcome (calibration). Internal validation was performed using bootstrapping analysis ( 15 ) . External validation was performed by applying the nomogram to patients in the validation cohort. All statistical analyses were two-sided and were performed using S-Plus software (PC version 3.3, Redmond, WA) with additional functions (called Design) ( 15 ) .
Disease progression was observed in 220 patients in the modeling cohort, and the 10-year progression-free probability was 77% (95% confi dence interval = 73% to 80%). A nomogram containing PSA ( P ≤ .001), clinical stage ( P ≤ .001), primary ( P ≤ .001) and secondary Gleason grade ( P ≤ .001), year of surgery ( P ≤ .001), and number of positive ( P = .25) and negative ( P = .094) biopsy cores had c-indices of 0.76 and 0.79 in internal and external validation, respectively. The nomogram estimates the 1-to 10-year progression-free probability after radical prostatectomy alone ( fi g1 Fig. 1, A ) . A model that did not include systematic biopsy results had an inferior predictive accuracy in external validation ( c-index = 0.77). The c-index value, which is similar to the area under the receiver operating characteristic curve, indicates that the nomogram performs slightly better than midway between a perfect model and a coin fl ip ( c -indices = 1.0 and 0.5, respectively).
The model exhibited good calibration across the spectrum of predictions in internal validation (data not shown) but exhibited some optimism in external validation; patients with an 8-year progression-free probability between 70% and 85% had an observed rate of freedom from progression of 57% -72% ( fi g1 Fig. 1, B ) . Part of the optimism may be explained by the fact that the model was developed on patients treated by highvolume surgeons and that the validation cohort was managed by both high-and low-volume surgeons. We have previously reported that positive surgical margins, which are associated with a threefold increased risk of recurrence, are infl uenced by surgeon volume and individual technique ( 16 , 17 ) . Surgeon volume may also be an independent predictor of recurrence ( 18 ) .
An added feature of the nomogram is the ability to estimate the probability of recurrence at any point in time from 1 to 10 years after radical prostatectomy. The ability to predict the risk of early recurrence may be important for neoadjuvant treatment strategies, because disease recurrence within 2 -3 years of radical prostatectomy is associated with an increased risk of metastasis progression and cancer-specifi c mortality ( 19 , 20 ) . Instructions for physician : Locate patient's preoperative prostate-specifi c antigen (PSA) on the Preoperative PSA axis. Draw a straight line down to the Points axis to determine how many points toward disease recurrence that patient receives. Repeat this process for each of the remaining variable axes. Sum the points for each predictor and locate this sum on the Total Points axis. Draw a line straight up from the Total Points axis until it intersects with the horizontal line drawn from Months from Surgery, corresponding to the time point in the future within which the risk of recurrence is wished to be calculated. The progression-free probability can be estimated at 12 to 120 months after radical prostatectomy. The slanted vertical line that crosses this intersection point corresponds to the calculated progression-free probability within that point in time after radical prostatectomy.
Instructions for patient : Mr. X, if we had 100 men exactly like you, we would predict <predicted probability from nomogram×100> percent to remain free of disease progression at <specifi ed months from surgery> following radical prostatectomy alone.
The nomogram predictions are adjusted for year of surgery, enabling the model to account for the improved prognosis of patients treated more recently. Of note, the nomogram assumes the patient is treated in 2003 and thus, theoretically, its accuracy for patients treated after 2003 is uncertain. However, we previously demonstrated that the improved prognosis associated with year of surgery is most pronounced for the years prior to 1998 and the hazard ratio is similar for the years 2000 -2003 ( 10 ) . Thus, the nomogram predictions are likely to be valid for patients treated after 2003. The current nomogram is most appropriate to use in regions where PSA screening is widespread ( 21 ) . The original nomogram may be better suited for use in non-PSA-screened patients given that it has been extensively validated in these populations ( 1 , 2 ) .
In a previous study, the percentage of positive biopsy cores did not improve the accuracy of the original nomogram ( 22 ) . The addition of the number of positive and negative biopsy cores to the current nomogram modestly increased its predictive accuracy. Neither parameter was statistically signifi cantly associated with recurrence in the model, but statistical signifi cance is not a prerequisite for improved outcome prediction ( 23 ) . We previously demonstrated that the length of cancer and noncancer in biopsy cores substantially enhanced the predictive accuracy of a nomogram for indolent prostate cancer ( 24 ) . Incorporation of these parameters into future nomograms is anticipated.
